High Throughput Screening
Venue: Crowne Plaza Hotel
|Event Date/Time: Apr 26, 2010||End Date/Time: Apr 27, 2010|
Hear from Peter Greasley, Lead Generation Science & Strategy Manger, AstraZeneca, and John Mathias, Head of HTS CoE, Pfizer, on how these two industry giants approach HTS for increasing lead generation potential. Learn about the contrasting abilities of virtual screening and HTS to provide leads â€“ where they agree and disagree, and how they can be used in conjunction. George Keseru, Head of Discovery Chemistry, Gedeon Richter will present a case study where virtual screening and HTS were carried out simultaneously, with very interesting results.
How you will benefit from attending this conference
â€¢ Hear from some of the most important and influential experts working in HTS
â€¢ Learn about changing the way we do HTS to increase the quality of lead generation
â€¢ Study what the realistic alternatives are to HTS, and what potential they hold
â€¢ Network with people you need to know in the HTS world
With new and more difficult target classes being studied more and more, there is a need for the standard assays used in HTS to be revisited and reworked to ensure that the leads generated are not misleading. One of the largest of these classes, GPCRs will be discussed by Michel Detheux of Euroscreen, who will present on optimising screening assays for orphan and liganded GPCRs.
Attend this event to discover how High Throughput Screening can be made more intelligent, more focussed and more beneficial in drug discovery.
Plus a Half-Day Post-Conference Workshop:
High Content Screening: Techniques, Strategies and Approaches
28th April 2010 â€“ Crowne Plaza Hotel â€“ St James, London
Hosted by Anthony Mitchell Davies, Director of the High Content Facility at the Institute of Molecular Medicine, Trinity College Dublin